0874 (0874) Fair Value & Analysis

Healthcare · Market cap HK$23.8B

0 0874 0874 · HK

PriceHK$14.21

Fair ValueHK$39.13

Upside+175.4%

Quality51/100

Evidence: Medium Range HK$28.49 – HK$49.77

Fair value as of: Jul 2, 2026

From 15 valuation models · updated today

Share price −5.0% over the past month.

Price vs Fair Value (12 months)

12‑month range HK$14.19 – HK$19.58 · fair‑value band HK$28.49 – HK$49.77 · the HK$14.21 price screens below the HK$39.13 fair value. As of Jul 2, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

0874 (0874) currently trades at HK$14.21, while our model-based Fair Value estimate is HK$39.13 — implying the stock looks roughly 175.4% undervalued today. We read business quality at 51/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium) — always confirm before acting.

Over the trailing twelve months, 0874 generated revenue of HK$78.5B at a net margin of 3.8%. Revenue grew 3.6% year over year. It earns a return on equity of 7.4%. Net debt stands at HK$5.8B. Fundamentals as of Jul 2, 2026

Key figures & financial health

Revenue (TTM) HK$78.5B

Revenue growth (YoY) +3.6%

Net margin 3.8%

Return on equity 7.4%

Free cash flow −HK$954M FY2025

P/E ratio 7.0

More key figures

Operating margin 9.4%

EPS (TTM) HK$1.98

Dividend yield 6.0%

EPS growth (YoY) -2.1%

Net debt HK$5.8B FY2025

Figures from reported company fundamentals (EODHD) · as of Jul 2, 2026. TTM = trailing twelve months.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

0874 reported revenue of HK$77.7B in FY2025 versus HK$69.0B in FY2021, a compound +3.0%/yr. Reported net income was HK$3.0B in FY2025, compounding −5.4%/yr from FY2021.

Revenue +3.0%/yr

FY21 HK$69.0B

FY22 HK$70.8B

FY23 HK$75.5B

FY24 HK$75.0B

FY25 HK$77.7B

Net income −5.4%/yr

FY21 HK$3.7B

FY22 HK$4.0B

FY23 HK$4.1B

FY24 HK$2.8B

FY25 HK$3.0B

Is 0874 fairly valued? → Check now

Similar stocks

6 more Medical Distribution stocks, each showing price versus our Fair Value estimate (as of Jul 2, 2026).

Stock	Price	Fair Value	vs Fair Value
McKesson Corporation M1CK34	R$958.36	R$188.90	-80%
Cencora, Inc C1CO34	R$707.04	R$79.88	-89%
Cardinal Health, Inc CAH	$222.74	$141.77	-36%
Sigma Healthcare Limited SIGGF	$2.35	$0.6300	-73%
Sitka Gold Corp SIG	A$2.92	A$1.20	-59%
Shanghai Pharmaceuticals Holding 601607	¥15.96	¥45.15	+183%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks

Frequently asked questions

Is 0874 (0874) undervalued?

As of Jul 2, 2026, our model estimates a fair value of HK$39.13 versus a price of HK$14.21 — about +175% (undervalued). Model-based estimate, not financial advice.

What is the fair value of 0874?

Our model-based fair value for 0874 is HK$39.13 (as of Jul 2, 2026), built from audited fundamentals. The current price is HK$14.21.

What is the quality score of 0874?

0874 has a Quality Score of 51/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

What is the revenue of 0874 (0874)?

0874 reported trailing-twelve-month revenue of about HK$78.5B (latest available figure, as of Jul 2, 2026).

What is the net profit margin of 0874?

The net profit margin of 0874 is about 3.8%, meaning it keeps roughly 3.8% of revenue as net income. Based on the latest reported figures.

Does 0874 pay a dividend?

0874 currently shows a dividend yield of about 5.98% relative to its recent price (as of Jul 2, 2026).

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.